{"id":"https://openalex.org/W2900511347","doi":"https://doi.org/10.1007/s00228-018-2581-7","title":"Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers","display_name":"Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers","publication_year":2018,"publication_date":"2018-11-15","ids":{"openalex":"https://openalex.org/W2900511347","doi":"https://doi.org/10.1007/s00228-018-2581-7","mag":"2900511347","pmid":"https://pubmed.ncbi.nlm.nih.gov/30443705"},"language":"en","primary_location":{"id":"doi:10.1007/s00228-018-2581-7","doi":"https://doi.org/10.1007/s00228-018-2581-7","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00228-018-2581-7","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00228-018-2581-7.pdf","source":{"id":"https://openalex.org/S31780008","display_name":"European Journal of Clinical Pharmacology","issn_l":"0031-6970","issn":["0031-6970","1432-1041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00228-018-2581-7.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041232510","display_name":"Gunilla Huledal","orcid":"https://orcid.org/0000-0001-8114-1486","observed_orcids":["https://orcid.org/0000-0001-8114-1486"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Gunilla Huledal","raw_affiliation_strings":["Sobi, SE-112 76, Stockholm, Sweden. gunilla.huledal@sobi.com","Sobi, SE-112 76, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sobi, SE-112 76, Stockholm, Sweden. gunilla.huledal@sobi.com","institution_ids":[]},{"raw_affiliation_string":"Sobi, SE-112 76, Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110503517","display_name":"Birgitta Olsson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Birgitta Olsson","raw_affiliation_strings":["Sobi, SE-112 76, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sobi, SE-112 76, Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053149949","display_name":"Kristin \u00d6nnestam","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristin \u00d6nnestam","raw_affiliation_strings":["Sobi, SE-112 76, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sobi, SE-112 76, Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112872367","display_name":"Per Dal\u00e9n","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Per Dal\u00e9n","raw_affiliation_strings":["Sobi, SE-112 76, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sobi, SE-112 76, Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Daniel Lindqvist","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Lindqvist","raw_affiliation_strings":["Sobi, SE-112 76, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sobi, SE-112 76, Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053809753","display_name":"Matthias Kruse","orcid":"https://orcid.org/0009-0002-0738-3174","observed_orcids":["https://orcid.org/0009-0002-0738-3174"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthias Kruse","raw_affiliation_strings":["PAREXEL International GmbH, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PAREXEL International GmbH, Berlin, Germany","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089414159","display_name":"Anders Br\u00f6ijers\u00e9n","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anders Br\u00f6ijers\u00e9n","raw_affiliation_strings":["Sobi, SE-112 76, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sobi, SE-112 76, Stockholm, Sweden","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5041232510"],"corresponding_institution_ids":[],"apc_list":{"value":3090,"currency":"USD","value_usd":3090},"apc_paid":{"value":3090,"currency":"USD","value_usd":3090},"fwci":0.7048,"has_fulltext":true,"cited_by_count":8,"citation_normalized_percentile":{"value":0.61118436,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"75","issue":"3","first_page":"313","last_page":"320"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nitisinone","display_name":"nitisinone","score":0.9959999918937683},{"id":"https://openalex.org/keywords/cytochrome-p450-inhibition","display_name":"cytochrome P450 inhibition","score":0.8370000123977661},{"id":"https://openalex.org/keywords/cyp2c9","display_name":"CYP2C9","score":0.9810000061988831},{"id":"https://openalex.org/keywords/cyp2d6","display_name":"CYP2D6","score":0.9919999837875366},{"id":"https://openalex.org/keywords/cyp2e1","display_name":"CYP2E1","score":0.9940000176429749},{"id":"https://openalex.org/keywords/organic-anion-transporters","display_name":"organic anion transporters","score":0.9380000233650208},{"id":"https://openalex.org/keywords/oat1","display_name":"OAT1","score":0.9990000128746033},{"id":"https://openalex.org/keywords/oat3","display_name":"OAT3","score":1.0},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.7480000257492065},{"id":"https://openalex.org/keywords/tolbutamide","display_name":"tolbutamide","score":0.8510000109672546},{"id":"https://openalex.org/keywords/metoprolol","display_name":"metoprolol","score":0.9950000047683716},{"id":"https://openalex.org/keywords/chlorzoxazone","display_name":"chlorzoxazone","score":0.9980000257492065},{"id":"https://openalex.org/keywords/furosemide","display_name":"furosemide","score":0.9990000128746033}],"concepts":[{"id":"https://openalex.org/C2776658834","wikidata":"https://www.wikidata.org/wiki/Q3294630","display_name":"Chlorzoxazone","level":5,"score":0.8351198434829712},{"id":"https://openalex.org/C123584848","wikidata":"https://www.wikidata.org/wiki/Q18034026","display_name":"Organic anion transporter 1","level":4,"score":0.8312265276908875},{"id":"https://openalex.org/C3946865","wikidata":"https://www.wikidata.org/wiki/Q5014962","display_name":"CYP2C9","level":4,"score":0.8200076818466187},{"id":"https://openalex.org/C2776054734","wikidata":"https://www.wikidata.org/wiki/Q414275","display_name":"Tolbutamide","level":3,"score":0.6872676610946655},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6570810675621033},{"id":"https://openalex.org/C33664856","wikidata":"https://www.wikidata.org/wiki/Q3271142","display_name":"CYP2D6","level":4,"score":0.5493516325950623},{"id":"https://openalex.org/C2777955127","wikidata":"https://www.wikidata.org/wiki/Q388801","display_name":"Furosemide","level":2,"score":0.5221196413040161},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4807046055793762},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4603251516819},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4189439117908478},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.41314855217933655},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.407328337430954},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3617306351661682},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.35615074634552},{"id":"https://openalex.org/C140027455","wikidata":"https://www.wikidata.org/wiki/Q14864434","display_name":"CYP2E1","level":4,"score":0.22514265775680542},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13188675045967102},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.12705400586128235},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.10633248090744019},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.07821094989776611},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003512","descriptor_name":"Cyclohexanones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003512","descriptor_name":"Cyclohexanones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D003512","descriptor_name":"Cyclohexanones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009579","descriptor_name":"Nitrobenzoates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009579","descriptor_name":"Nitrobenzoates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D009579","descriptor_name":"Nitrobenzoates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013379","descriptor_name":"Substrate Specificity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019389","descriptor_name":"Cytochrome P-450 CYP2D6","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019392","descriptor_name":"Cytochrome P-450 CYP2E1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D027362","descriptor_name":"Organic Anion Transport Protein 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D029362","descriptor_name":"Organic Anion Transporters, Sodium-Independent","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065729","descriptor_name":"Cytochrome P-450 CYP2C9","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00228-018-2581-7","doi":"https://doi.org/10.1007/s00228-018-2581-7","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00228-018-2581-7","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00228-018-2581-7.pdf","source":{"id":"https://openalex.org/S31780008","display_name":"European Journal of Clinical Pharmacology","issn_l":"0031-6970","issn":["0031-6970","1432-1041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:30443705","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30443705","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of clinical pharmacology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1007/s00228-018-2581-7","doi":"https://doi.org/10.1007/s00228-018-2581-7","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00228-018-2581-7","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00228-018-2581-7.pdf","source":{"id":"https://openalex.org/S31780008","display_name":"European Journal of Clinical Pharmacology","issn_l":"0031-6970","issn":["0031-6970","1432-1041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320327470","display_name":"Swedish Orphan Biovitrum","ror":"https://ror.org/04asvbz37"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2900511347.pdf","grobid_xml":"https://content.openalex.org/works/W2900511347.grobid-xml"},"referenced_works_count":13,"referenced_works":["https://openalex.org/W179252842","https://openalex.org/W185271959","https://openalex.org/W1510018222","https://openalex.org/W1967141222","https://openalex.org/W2019742973","https://openalex.org/W2029388610","https://openalex.org/W2035948624","https://openalex.org/W2057449776","https://openalex.org/W2097721154","https://openalex.org/W2121074897","https://openalex.org/W2125674718","https://openalex.org/W2145611140","https://openalex.org/W2743420965"],"related_works":["https://openalex.org/W4387393335","https://openalex.org/W2002109437","https://openalex.org/W2044556570","https://openalex.org/W2187304469","https://openalex.org/W2148320771","https://openalex.org/W2008146007","https://openalex.org/W1907053176","https://openalex.org/W2392387368","https://openalex.org/W4214705122","https://openalex.org/W2998886635"],"abstract_inverted_index":{"Nitisinone":[0,112,201,222],"inhibits":[1],"the":[2,12,25,39,47,79,85,107],"cytochrome":[3],"P450":[4],"(CYP)":[5],"subfamilies":[6,54],"CYP2C9,":[7,228],"CYP2D6,":[8],"and":[9,11,19,32,55,76,82,93,115,120,122,129,169,195,213,220,229],"CYP2E1":[10],"organic":[13],"anion":[14],"transporter":[15],"(OAT)":[16],"isoforms":[17],"OAT1":[18,219],"OAT3":[20],"in":[21,34,69,142,234],"vitro":[22],".":[23],"Since":[24],"effect":[26,48],"of":[27,41,49,97,101,187,211,218,227,238],"nitisinone":[28,50,130,176],"on":[29,51],"these":[30,52],"enzymes":[31],"transporters":[33],"humans":[35],"is":[36],"still":[37],"unknown,":[38],"purpose":[40],"this":[42,243],"study":[43,66],"was":[44,59,156,207,214,223],"to":[45,105,126],"evaluate":[46],"CYP":[53],"OAT":[56],"isoforms.":[57],"This":[58],"an":[60],"open-label,":[61],"nonrandomized,":[62],"two-arm,":[63],"phase":[64],"1":[65],"(EudraCT:":[67],"2016-004297-17)":[68],"healthy":[70],"volunteers.":[71],"The":[72,145],"substrates":[73],"(tolbutamide,":[74],"metoprolol,":[75,164],"chlorzoxazone":[77],"for":[78,84,153,159,163,167,172],"respective":[80],"CYPs":[81],"furosemide":[83],"OATs)":[86],"were":[87,117,124,136,179,192,199],"administered":[88],"as":[89],"single":[90],"doses,":[91],"before":[92],"after":[94,181],"15":[95],"days":[96],"once":[98],"daily":[99],"dosing":[100],"80":[102],"mg":[103],"nitisinone,":[104],"determine":[106,127],"AUC":[108,154],"\u221e":[109,155],"ratios":[110],"([substrate+nitisinone]/[substrate]).":[111],"pharmacokinetics,":[113],"safety,":[114],"tolerability":[116],"also":[118],"assessed,":[119],"blood":[121],"urine":[123],"collected":[125],"substrate":[128],"concentrations":[131,178,237],"by":[132],"LC-MS/MS.":[133],"Thirty-six":[134],"subjects":[135,140],"enrolled":[137],"with":[138],"18":[139],"included":[141],"each":[143],"arm.":[144],"least":[146],"square":[147],"mean":[148,184],"ratio":[149],"(90%":[150],"confidence":[151],"interval)":[152],"2.31":[157],"(2.11\u20132.53)":[158],"tolbutamide,":[160],"0.95":[161],"(0.88\u20131.03)":[162],"0.73":[165],"(0.67\u20130.80)":[166],"chlorzoxazone,":[168],"1.72":[170],"(1.63\u20131.81)":[171],"furosemide.":[173],"Clinically":[174],"relevant":[175],"steady-state":[177],"reached":[180],"12":[182],"days:":[183],"C":[185],"av,ss":[186],"94.08":[188],"\u03bcM.":[189],"All":[190],"treatments":[191],"well":[193],"tolerated,":[194],"no":[196],"safety":[197],"concerns":[198],"identified.":[200],"did":[202],"not":[203],"affect":[204],"CYP2D6":[205],"activity,":[206],"a":[208,215,224],"weak":[209,216],"inducer":[210],"CYP2E1,":[212],"inhibitor":[217,226],"OAT3.":[221],"moderate":[225],"treatment":[230],"may":[231],"therefore":[232],"result":[233],"increased":[235],"plasma":[236],"comedications":[239],"metabolized":[240],"primarily":[241],"via":[242],"enzyme.":[244],"EudraCT":[245],"2016-004297-17.":[246]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-11-29T00:00:00"}